Free tool
FAERS Monitor: Pepcid Ac
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020325 or its brand name (Pepcid Ac, Famotidine). Reports on generic versions are filed under their own applications.
Reports
84,762
Serious
56,219
66% of reports
Hospitalization
28,101
Death reported
8,065
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea5,480
- fatigue5,226
- diarrhoea5,095
- chronic kidney disease4,686
- off label use4,432
- drug ineffective4,253
- dyspnoea4,008
- headache3,755
- acute kidney injury3,418
- vomiting3,320
- pain3,257
- dizziness3,157
- death2,857
- pneumonia2,735
- pyrexia2,668
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 743 |
| 2005 | 736 |
| 2006 | 692 |
| 2007 | 679 |
| 2008 | 850 |
| 2009 | 721 |
| 2010 | 1,023 |
| 2011 | 1,563 |
| 2012 | 1,933 |
| 2013 | 1,154 |
| 2014 | 1,431 |
| 2015 | 2,552 |
| 2016 | 3,020 |
| 2017 | 3,301 |
| 2018 | 4,644 |
| 2019 | 5,538 |
| 2020 | 6,658 |
| 2021 | 6,825 |
| 2022 | 7,306 |
| 2023 | 7,406 |
| 2024 | 8,625 |
| 2025 | 9,592 |
| 2026 | 7,766 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,969,397 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chronic kidney diseaseSignal | 4,686 | 16.2 | 15.8 | 63,114 |
| acute kidney injurySignal | 3,418 | 5.6 | 5.5 | 12,865 |
| pneumoniaSignal | 2,735 | 2.1 | 2.0 | 1,598 |
| diarrhoea | 5,095 | 2.0 | 1.9 | 2,475 |
| pyrexia | 2,668 | 1.9 | 1.8 | 1,186 |
| dyspnoea | 4,008 | 1.8 | 1.7 | 1,348 |
| vomiting | 3,320 | 1.8 | 1.7 | 1,100 |
| nausea | 5,480 | 1.7 | 1.7 | 1,715 |
| fatigue | 5,226 | 1.7 | 1.6 | 1,449 |
| dizziness | 3,157 | 1.6 | 1.5 | 673 |
| headache | 3,755 | 1.5 | 1.4 | 618 |
| pain | 3,257 | 1.3 | 1.3 | 255 |
| off label use | 4,432 | 1.3 | 1.2 | 242 |
| death | 2,857 | 0.8 | 0.8 | 114 |
| drug ineffective | 4,253 | 0.8 | 0.8 | 226 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.